Researchers have long used imaging technology to try to understand mental-health ailments. But with relatively few participants, such studies may not be producing valid findings.
As brain scans have become more detailed and informative in recent decades, neuroimaging has seemed to promise a way for doctors and scientists to “see” what’s going wrong inside the brains of people with mental illnesses or neurological conditions. Such imaging has revealed correlations between brain anatomy or function and illness, suggesting potential new ways […]
Every two weeks, a nurse visits 43-year-old Marty Reiswig in Denver, Colorado, and injects him with an experimental drug called gantenerumab. Every month, Reiswig drives into town for a brain scan to make sure the drug has not caused any bleeds. And every year he flies to St Louis, Missouri, for four days of brain […]
The TV sitcom grandpa character who always seems to fall asleep at unfortunate moments is so common it’s almost a cliché. But daytime napping and disjointed sleep at night aren’t normal parts of aging. Sleep disturbances can be an early sign of a neurodegenerative condition, and they may be treatable.
A large study that investigates just what keeps our brains sharp as we age and what contributes to cognitive decline has been launched by researchers from Washington University School of Medicine in St. Louis, Harvard University/Massachusetts General Hospital, the University of Minnesota Medical School and the University of California Los Angeles (UCLA).
A blood test developed at Washington University School of Medicine in St. Louis has proven highly accurate in detecting early signs of Alzheimer’s disease in a study involving nearly 500 patients from across three continents, providing further evidence that the test should be considered for routine screening and diagnosis.
The Alzheimer’s Association, with GHR Foundation and Edward Jones, announced a $14 million commitment in support of Washington University’s Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) Primary Prevention Trial.
Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10% of patients surviving longer than five years after diagnosis.
Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold — up to 25 years before the […]
Longtime St. Louis benefactor Joanne Knight has committed up to $11.5 million to Washington University School of Medicine in St. Louis to support an innovative clinical trial aimed at preventing Alzheimer’s disease by treating people before the first signs of the illness appear in the brain.